Clinical trial
Bevacizumab for the Treatment of Cerebral RAdiation Induced NecrosiS (BRAINS) Study: a Multicenter, Open-label, Randomized Clinical Trial to Assess the Clinical Efficacy and Cost-effectiveness of Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
NCT06888817 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Bevacizumab for the Treatment of Cerebral RAdiation Induced NecrosiS (BRAINS) Study: a Multicenter, Open-label, Randomized Clinical Trial to Assess the Clinical Efficacy and Cost-effectiveness of Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
- Lead sponsor
- The Netherlands Cancer Institute
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- June 19, 2025
- Completion date
- July 31, 2030
- Enrollment
- 408 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
brain metastasases, high grade glioma (iii or iv), radiation effect, radiation injuries, radiation injury, radiation necrosis, radiation toxicity